Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc., filed a Form 4 on October 30, 2026, disclosing the sale of 753 shares of common stock on October 28, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Key Highlights

  • Reporting person: Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc. (NASDAQ:RLAY)
  • Transaction: 753 shares of common stock disposed of (transaction code S) on October 28, 2026, at a price of $18.62 per share
  • RSU vesting: 3,051 shares of restricted stock units vested on October 27, 2026, triggering the tax-withholding sale
  • No discretion: According to the filing, the sale was transacted in accordance with the issuer's policies regarding RSU vesting and the reporting person "had no discretion with respect to such sale"
  • Beneficial ownership following transaction: 222,904 shares, held directly, including 3,051 shares underlying RSUs

Peter Rahmer's RSU-Related Share Sale at Relay Therapeutics

According to the Form 4 filed on October 30, 2026, Peter Rahmer, identified in the filing as Chief Corporate Development Officer of Relay Therapeutics, Inc. (NASDAQ:RLAY), disposed of 753 shares of common stock on October 28, 2026, at a price of $18.62 per share. The filing describes the transaction as a sale to cover the reporting person's income tax withholding obligations arising from the vesting of 3,051 restricted stock units on October 27, 2026.

The filing states that the reporting person "had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs." The transaction is coded as an S (open-market or private sale) in Table I of the form. No Rule 10b5-1 plan box is checked on the form in connection with this transaction.

Following the reported transaction, the filing discloses that Rahmer directly and beneficially owned 222,904 shares of Relay Therapeutics common stock, a figure that the filing notes includes 3,051 shares underlying RSUs. The form was signed by Soo-Yeun Lim as Attorney-in-Fact on October 30, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, filed a Form 4 reporting the sale of 753 common shares at $18.62 on October 28, 2026, solely to satisfy tax withholding upon the vesting of 3,051 RSUs, leaving him with 222,904 shares beneficially owned.